newsfilter
← Latest News
GlobeNewswire·

OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

  • OKYO Pharma Limited (Nasdaq: OKYO) has transitioned its At-The-Market (ATM) equity offering facility from B. Riley Securities Inc. to Leerink Partners LLC.
  • Leerink Partners will act as the exclusive sales agent receiving a 3.0% commission on gross proceeds from any shares sold under the program.
  • The new ATM arrangement enables OKYO Pharma to sell common shares opportunistically at prevailing market prices to support clinical development & corporate objectives.
  • CFO Keeren Shah cited Leerink's biotech expertise & investor relationships as key factors for the partnership to advance the urcosimod pipeline.
  • Sales under the program will be conducted pursuant to a prospectus supplement & base prospectus filed with the U.S. Securities and Exchange Commission (SEC).
  • OKYO Pharma recently completed a Phase 2 trial for urcosimod in neuropathic corneal pain (NCP) patients & plans to initiate a Phase 2b/3 study of ~150 subjects in the first half of 2026.
  • The press release includes standard forward-looking statement disclaimers regarding risks & uncertainties associated with future clinical outcomes & capital markets.